Multiple myeloma classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:


==Classification==
==Classification==
*Multiple myeloma is classified according to the extent of organ involvement into two subgroups:<ref name="pmid10357398">{{cite journal| author=Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B et al.| title=Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. | journal=Cancer | year= 1999 | volume= 85 | issue= 11 | pages= 2305-14 | pmid=10357398 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10357398  }} </ref>
Plasma cell disorders such as multiple myeloma and its related diseases are classified according to disease burden and the extent of organ involvement.
:#Medullary multiple myeloma
:#Extramedullary multiple myeloma


*Multiple myeloma may be classified according to clinical presentation into two subgroups:<ref name"wiki"=>Multiple myeloma. Wikipedia(2015) https://en.wikipedia.org/wiki/Multiple_myeloma#Diagnostic_criteria Accessed on September, 20th 2015<nowiki></ref></nowiki><ref>Treatment guide active multiple myeloma. National comprehensive cancer network(2015) http://www.nccn.org/patients/guidelines/myeloma/#44/z Accessed on September, 20th 2015</ref><ref>Treatment guide smoldering multiple myeloma. National comprehensive cancer network(2015) http://www.nccn.org/patients/guidelines/myeloma/#44/z Accessed on September, 20th 2015</ref>
 
:#Active symptomatic multiple myeloma
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center
:#Smoldering asymptomatic multiple myeloma
|valign=top|
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Disease}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Diagnostic Criteria}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Management Approach}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
[[Solitary plasmacytoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
Biopsy of solid mass showing clonal plasma cells
| style="padding: 5px 5px; background: #F5F5F5;" |
Radiation therapy
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
[[Monoclonal gammopathy of undetermined significance]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*Presence of M-spike that quantitates < 3 g/dl on protein electrophoresis, ''or''
*Presence of bone marrow plasma cell burden of < 10%
''plus''
*Absence of end-organ damage such as anemia, hypercalcemia, renal dysfunction, or osseous lesions
| style="padding: 5px 5px; background: #F5F5F5;" |
Monitoring of [[complete blood count]] every 6-12 months
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
[[Smoldering multiple myeloma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*Presence of M-spike that quantitates > 3 g/dl on protein electrophoresis, ''or''
*Presence of bone marrow plasma cell burden of > 10% but < 60%
''plus''
*Absence of end-organ damage such as anemia, hypercalcemia, renal dysfunction, or osseous lesions
| style="padding: 5px 5px; background: #F5F5F5;" |
Monitoring of [[complete blood count]] at specified intervals, depending on risk stratification
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
[[Active multiple myeloma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*Presence of M-spike that quantitates > 3 g/dl on protein electrophoresis, ''or''
*Presence of bone marrow plasma cell burden of > 10% but < 60%
''plus''
*Presence of at least one of the following: anemia, hypercalcemia, renal dysfunction, osseous lesions, bone marrow plasma cell burden > 60%, serum free light chain ratio (of involved to uninvolved light chain) > 100, MRI showing > 1 bony lesion of at least 5mm
| style="padding: 5px 5px; background: #F5F5F5;" |
*Induction chemotherapy with bortezomib, lenalidomide, and dexamethasone
*High-dose therapy plus autologous stem cell transplantation
*Post-transplant lenalidomide maintenance
(''Please see Therapy section for details''
|-
|}


==References==
==References==

Revision as of 04:27, 15 July 2018

Multiple myeloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple Myeloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Multiple myeloma classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple myeloma classification

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple myeloma classification

CDC on Multiple myeloma classification

Multiple myeloma classification in the news

Blogs on Multiple myeloma classification

Directions to Hospitals Treating Multiple myeloma

Risk calculators and risk factors for Multiple myeloma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Multiple myeloma may be classified into several subtypes based on the extent of organ involvement (medullary or extramedullary) and the disease clinical presentation(active symptomatic or smoldering asymptomatic).[1]

Classification

Plasma cell disorders such as multiple myeloma and its related diseases are classified according to disease burden and the extent of organ involvement.


Disease Diagnostic Criteria Management Approach

Solitary plasmacytoma

Biopsy of solid mass showing clonal plasma cells

Radiation therapy

Monoclonal gammopathy of undetermined significance

  • Presence of M-spike that quantitates < 3 g/dl on protein electrophoresis, or
  • Presence of bone marrow plasma cell burden of < 10%

plus

  • Absence of end-organ damage such as anemia, hypercalcemia, renal dysfunction, or osseous lesions

Monitoring of complete blood count every 6-12 months

Smoldering multiple myeloma

  • Presence of M-spike that quantitates > 3 g/dl on protein electrophoresis, or
  • Presence of bone marrow plasma cell burden of > 10% but < 60%

plus

  • Absence of end-organ damage such as anemia, hypercalcemia, renal dysfunction, or osseous lesions

Monitoring of complete blood count at specified intervals, depending on risk stratification

Active multiple myeloma

  • Presence of M-spike that quantitates > 3 g/dl on protein electrophoresis, or
  • Presence of bone marrow plasma cell burden of > 10% but < 60%

plus

  • Presence of at least one of the following: anemia, hypercalcemia, renal dysfunction, osseous lesions, bone marrow plasma cell burden > 60%, serum free light chain ratio (of involved to uninvolved light chain) > 100, MRI showing > 1 bony lesion of at least 5mm
  • Induction chemotherapy with bortezomib, lenalidomide, and dexamethasone
  • High-dose therapy plus autologous stem cell transplantation
  • Post-transplant lenalidomide maintenance

(Please see Therapy section for details

References

  1. Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B; et al. (1999). "Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts". Cancer. 85 (11): 2305–14. PMID 10357398.


Template:WikiDoc Sources